Recurrent Implantation Failure — Causes, Evaluation, and Evidence-Based Treatment

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Recurrent implantation failure evaluation and treatment requires individualized clinical assessment. The evidence base for many RIF interventions is actively evolving — discuss all treatment decisions with a qualified reproductive endocrinologist.

Experiencing two or three failed embryo transfers when the embryos appeared to be of good quality is one of the most emotionally draining situations in fertility medicine. It raises the question that practitioners and patients both struggle with: if the embryos look normal, why isn't implantation happening?

Recurrent implantation failure (RIF) sits at the intersection of embryo quality, uterine biology, and — more controversially — immune function. The evidence base is patchy in some areas, and there is a meaningful risk of pursuing unproven add-on treatments out of desperation. This guide navigates the evidence honestly: what we know, what we suspect, and what remains speculative.

Defining Recurrent Implantation Failure

There is no universally agreed definition of RIF, which itself complicates the research. The most widely cited working definition, used in the 2023 ESHRE guideline on RIF, is:

Failure to achieve a clinical pregnancy after transfer of at least two (some guidelines say three) good-quality embryos in a woman under 40, with a morphologically normal uterine cavity.

Some definitions specify blastocyst-stage embryos; others include cleavage-stage embryos. Some require documented absence of chromosomal abnormality (i.e., PGT-A tested normal embryos). The inclusion criteria matter because the natural rate of IVF failure is high — approximately 50–70% of transfers fail even with good-quality embryos, largely due to embryo aneuploidy — meaning some "RIF" diagnoses represent statistical bad luck with aneuploid embryos rather than a true implantation defect.

This is why ESHRE and many fertility societies now recommend ruling out embryo aneuploidy (via PGT-A) before pursuing an extensive immunological or uterine work-up. Transferring euploid (chromosomally normal) embryos that fail to implant is a more rigorous definition of true RIF.

The Causes: A Framework

Causes of RIF broadly fall into three categories:

1. Embryo factors — the embryo itself is the primary problem (even if it looks morphologically normal)
2. Uterine factors — the endometrium or uterine anatomy prevents implantation
3. Immunological and other systemic factors — immune dysfunction, thrombophilias, or lifestyle factors

In clinical practice, the causes often coexist and interact. No single cause is found in the majority of RIF patients — a frustrating reality that drives the proliferation of empirical treatments.

Embryo Factors

Occult Aneuploidy

The most common reason a good-looking embryo fails to implant is chromosomal abnormality (aneuploidy) that cannot be detected by conventional morphology grading. A Day 5 blastocyst scored AA (top grade by Gardner criteria) can still be aneuploid — and aneuploid embryos almost never result in a clinical pregnancy.

The proportion of embryos that are aneuploid increases dramatically with maternal age:

• Under 35: approximately 30–40% of blastocysts aneuploid
• 35–37: approximately 40–50%
• 38–40: approximately 50–60%
• Over 40: approximately 60–80% or higher

This means that in an older patient who has experienced multiple fresh or frozen transfers without PGT-A, the most likely explanation is not a uterine problem but the repeated transfer of aneuploid embryos. PGT-A is not a perfect test (mosaicism, biopsy error, and segmental aneuploidies create complexity), but identifying euploid embryos substantially changes the probability landscape.

For an overview of how IVF success rates interact with age and embryo genetics, see our guide on reading clinic data.

Sperm DNA Fragmentation

Sperm DNA fragmentation (SDF) has emerged as an important and underrecognized embryo-quality factor. Sperm that carry fragmented DNA can fertilize eggs and produce morphologically normal embryos, but those embryos are more likely to arrest in culture, fail to implant, or miscarry after implantation.

SDF is measured by the DNA Fragmentation Index (DFI) using tests such as TUNEL, SCSA, or SCD (Sperm Chromatin Dispersion). A DFI above approximately 15–25% (threshold varies by assay) is considered elevated and associated with poorer IVF outcomes.

Evidence from multiple studies and a 2019 ASRM committee opinion supports measuring SDF in:

• Couples with RIF
• Couples with recurrent pregnancy loss
• Men with unexplained infertility or normal semen parameters but poor IVF outcomes

Treatment options for elevated SDF include:

• Lifestyle modification: Reducing oxidative stress (smoking cessation, antioxidant supplementation, heat avoidance) can modestly reduce SDF over the 90-day spermatogenic cycle
• Testicular sperm extraction (TESE): Testicular sperm has substantially lower SDF than ejaculated sperm in men with high SDF; using TESE sperm for ICSI may improve embryo quality
• ICSI with microfluidic sperm selection or IMSI (high-magnification ICSI): Evidence for these techniques improving outcomes in RIF remains limited; not yet standard of care

Uterine Factors

Submucosal Fibroids

Submucosal fibroids — fibroids that protrude into the uterine cavity — are the most clearly established uterine cause of implantation failure. Multiple studies and a Cochrane systematic review confirm that submucosal fibroids significantly reduce IVF success rates (by approximately 50% in some estimates), and surgical removal (hysteroscopic myomectomy) restores outcomes close to baseline.

The evidence for intramural fibroids (within the muscle wall, not distorting the cavity) is more ambiguous. Large intramural fibroids (>4 cm) with any cavity distortion likely warrant treatment; smaller intramural fibroids without cavity involvement are controversial.

Endometrial Polyps

Endometrial polyps are focal overgrowths of the uterine lining that may project into the cavity and mechanically impair implantation or alter the local hormonal environment. The TROPHY trial (randomized controlled trial, published 2022 in NEJM Evidence) demonstrated that hysteroscopic removal of polyps before IVF significantly improved live birth rates compared to diagnostic hysteroscopy without removal.

This is one of the cleaner pieces of evidence in RIF management: if a polyp is found on saline-infused sonography (SIS) or hysteroscopy, removal before IVF or FET transfer cycles is warranted.

Intrauterine Adhesions (Asherman's Syndrome)

Adhesions within the uterine cavity — typically from prior uterine surgery, D&C, or endometritis — can reduce the functional endometrial surface and impair implantation. Diagnosis is by hysteroscopy (the gold standard). Treatment is hysteroscopic adhesiolysis, though outcomes depend heavily on the severity and extent of adhesions, and recurrence is common in severe cases.

Thin Endometrial Lining

An endometrial thickness below 7 mm on the day of progesterone initiation or trigger is associated with lower implantation rates in most (though not all) studies. Severe thinning (<6 mm) is particularly concerning.

Causes include:

• Prior uterine surgery or infection damaging the basal endometrium
• Reduced uterine blood flow
• Inadequate estrogen (unusual with standard FET medication doses)
• Asherman's syndrome (above)

Interventions for thin endometrium are largely empirical and incompletely proven:

• Extended estrogen priming — increasing dose or duration; evidence is limited
• Vaginal sildenafil — increases uterine blood flow via vasodilation; small studies show promise but RCT evidence is lacking
• Platelet-rich plasma (PRP) intrauterine infusion — injecting centrifuged platelet-concentrated plasma into the uterine cavity; several small studies suggest improved thickness and pregnancy rates, but the evidence base is still building and PRP is not yet standard of care
• Low-dose aspirin — sometimes used to improve uterine blood flow; evidence is weak

Hydrosalpinx

Hydrosalpinx — fluid-filled, blocked fallopian tubes — is a well-documented cause of IVF failure. Tubal fluid draining into the uterine cavity is embryotoxic and may mechanically flush out transferred embryos. Surgical treatment (salpingectomy or proximal tubal occlusion) before IVF in women with hydrosalpinx improves live birth rates significantly — this is one of the strongest evidence-based interventions in RIF management.

Evaluation Protocol for RIF

The 2023 ESHRE guideline on RIF recommends a structured evaluation covering:

ERA Testing: Evidence and Limitations

The Endometrial Receptivity Analysis (ERA) test is a molecular diagnostic tool that analyzes the expression of 236 genes in an endometrial biopsy to determine whether the endometrium is in a "receptive" or "non-receptive" state on a given day of progesterone exposure. If the window of implantation (WOI) is displaced, the ERA report suggests a personalized embryo transfer (pET) — transferring one day earlier or later than the standard day.

The evidence: The ERA was developed by Igenomix (now Vitrolife) and initial observational studies showed promise. However, the pivotal prospective randomized trial — the iReceptive trial (published in NEJM Evidence, 2023) — found that ERA-guided transfer did not significantly improve live birth rates compared to standard protocol in a general unselected FET population.

Current clinical position: The ESHRE guideline on RIF (2023) states that ERA testing may be considered in RIF patients with two or more failed euploid embryo transfers, acknowledging that the WOI displacement rate is higher in RIF populations (approximately 20–25%) than in the general IVF population. It is not recommended as a routine investigation for all IVF patients.

The honest summary: ERA is a biologically plausible test targeting a real phenomenon, but its clinical utility — particularly in unselected patients — has not been established in randomized controlled trials. In true RIF (failed euploid transfers), it remains a reasonable diagnostic consideration with the caveat that it adds cost and an additional cycle delay.

Immunological Factors: What the Evidence Actually Shows

This is the most contested area of RIF medicine, and the one where patients are most vulnerable to expensive unproven treatments. It requires particularly careful epistemic humility.

Antiphospholipid Antibody Syndrome (APS)

APS is a genuine, well-established thrombophilia associated with recurrent pregnancy loss and possibly implantation failure. Testing for antiphospholipid antibodies (anticardiolipin, anti-beta2 glycoprotein I, lupus anticoagulant) is well-evidenced in RIF work-up. Treatment with low-molecular-weight heparin (LMWH) and low-dose aspirin is standard of care when APS is confirmed.

Other Heritable Thrombophilias (Factor V Leiden, MTHFR, etc.)

The evidence supporting treatment of other thrombophilias (Factor V Leiden heterozygosity, MTHFR mutations, Protein S/C deficiency) in RIF is substantially weaker. MTHFR polymorphisms in particular — frequently cited in "functional medicine" fertility circles — have not been consistently linked to implantation failure, and supplementing high-dose folate or methylfolate for MTHFR variants is not supported by evidence in this context. The ASRM does not recommend routine thrombophilia screening for IVF patients without a history of venous thromboembolism or recurrent pregnancy loss.

Uterine Natural Killer Cells (uNK)

Elevated uterine natural killer (uNK) cells have been proposed as a cause of RIF. uNK cells are assessed by endometrial biopsy, and elevated CD56+ counts have been reported in some RIF patients. However:

• The reference ranges for "elevated" uNK are not standardized across labs
• The biological role of uNK in implantation is complex — uNK cells are normally present at the implantation site and play a supportive role in placentation; their elevation may be a marker rather than a cause
• RCT evidence for treatments targeting uNK (intralipid infusion, prednisolone) is very limited and the existing trials are small and methodologically weak

The ESHRE 2023 RIF guideline explicitly states that uNK cell testing should not be performed outside of research settings due to the lack of standardized methodology and evidence-based treatment. Patients should be cautious about clinics that offer uNK testing and empirical immunosuppression as a routine RIF protocol.

Intravenous Intralipid (IL)

Intralipid infusion has been proposed to suppress natural killer cell activity. The evidence base is predominantly from small, uncontrolled studies. The largest randomized trial (by Moffett et al.) did not show a significant benefit. Intralipid is not recommended outside of research protocols by ASRM or ESHRE.

Prednisolone and Immunosuppression

Some clinics offer empirical prednisolone (oral corticosteroid) during FET to reduce implantation-disrupting immune responses. Again, RCT evidence is limited and contradictory. A 2022 Cochrane review found insufficient evidence to recommend prednisolone supplementation in RIF, and noted potential risks of corticosteroid exposure in early pregnancy.

What Has Evidence vs. What Doesn't

Frequently Asked Questions

Q: How is recurrent implantation failure defined, and how many failed transfers does it take? A: There is no universally agreed threshold. The 2023 ESHRE guideline defines RIF as failure to achieve clinical pregnancy after transfer of at least two good-quality blastocysts (or equivalent number of cleavage-stage embryos). Many clinicians prefer using this definition only after at least one or two transfers of PGT-A confirmed euploid embryos, since natural aneuploidy rates in untested embryos explain many failed transfers statistically. The "true RIF" — failed euploid embryo transfers — is a more specific and clinically meaningful diagnosis.

Q: Should I have an ERA test after two failed transfers? A: The ERA test is not supported by RCT evidence as a routine investigation for all IVF patients — the iReceptive trial (NEJM Evidence, 2023) did not show improved live birth rates. However, ESHRE acknowledges that in true RIF (particularly after two or more failed euploid transfers), the displaced window of implantation rate may be higher (~20–25%), and ERA is a reasonable diagnostic consideration. Discuss the expected probability of an abnormal result, the limitations of the test, and the additional cost and cycle delay with your specialist before proceeding.

Q: Do NK cells cause implantation failure, and should I be tested? A: This is an area of active research and significant controversy. Uterine NK cells are a normal and important component of the endometrial immune environment. Elevated uNK cell counts have been reported in some RIF patients, but testing is not standardized, reference ranges vary between labs, and there is no robust RCT evidence that treating elevated uNK cells improves live birth rates. The ESHRE 2023 RIF guideline recommends against routine uNK testing outside research settings. Patients should be cautious about clinics offering this testing as standard care paired with empirical immunosuppression.

Q: Can sperm DNA fragmentation cause implantation failure even when semen analysis is normal? A: Yes. Sperm DNA fragmentation can occur even when sperm count, motility, and morphology appear normal on a standard semen analysis. Fragmented sperm DNA can fertilize an egg and produce morphologically graded embryos that fail to implant or miscarry — the damage is not visible on routine assessment. Testing sperm DNA fragmentation (via SCSA, TUNEL, or SCD assay) is recommended by ASRM in couples with RIF, recurrent pregnancy loss, or unexplained IVF failure despite good embryo grades.

Q: What is the most important first step in evaluating RIF? A: Before embarking on an extensive immunological work-up, ESHRE and ASRM both recommend: (1) Confirming the uterine cavity is normal using saline-infused sonography or diagnostic hysteroscopy — uterine abnormalities are the most actionable and evidence-supported finding; and (2) If not already done, proceeding with PGT-A to confirm that transferred embryos are chromosomally normal. A significant proportion of apparent RIF resolves when euploid-confirmed embryos are transferred, highlighting that occult aneuploidy explains many cases that look like implantation failure.

Sources

• ESHRE Working Group on Recurrent Implantation Failure. "ESHRE guideline on recurrent implantation failure." Hum Reprod Open. 2023;2023(3):hoad023.
• Coughlan C, et al. "Recurrent implantation failure: definition and management." Reprod Biomed Online. 2014;28(1):14–38.
• Polanski LT, et al. "What exactly do we mean by 'recurrent implantation failure'? A systematic review." Reprod Biomed Online. 2014;28(4):409–423.
• Bhatt DL (TROPHY trial). "Hysteroscopic treatment of endometrial polyps in subfertile women." NEJM Evidence. 2022;1(1).
• Ruiz-Alonso M, et al. "The ERA test — clinical utility." Fertil Steril. 2013;100(6):1553–1561.
• Carosso AR, et al. "ERA test in the context of recurrent implantation failure." NEJM Evidence. 2023.
• Zhu L, et al. "Elevated sperm DNA fragmentation in IVF patients with RIF." J Assist Reprod Genet. 2018;35(4):609–616.
• ASRM Practice Committee. "Sperm DNA fragmentation testing." Fertil Steril. 2019;111(5):873–881.
• Moffett A, et al. "Uterine natural killer cells and reproductive success." Nat Rev Immunol. 2020;20(10):643–652.
• Seshadri S, et al. "Intralipid in assisted reproduction: a systematic review." Reprod Biomed Online. 2016;33(4):400–410.
• Quenby S, et al. "Prednisolone in RIF — Cochrane review." Cochrane Database Syst Rev. 2022.